DNA damage response company Artios Pharma Limited revealed on Monday the addition of Professor Rajesh Chopra PhD as a non-executive director (NED).

Recently, Dr Chopra has served as the corporate vice president of Translational Research at Celgene, where he led US and European teams of scientists in San Diego, San Francisco and Seville and clinicians from discovery to proof-of-concept clinical trials in oncology and immune/inflammatory diseases and stem cell therapies.

Previously, Dr Chopra was part of the oncology leadership team at AstraZeneca, where he established the Translational Medicine Group in Boston, Massachusetts.

Currently, Dr Chopra is head of the Division of Cancer Therapeutics and director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London.